Against the backdrop of DRG/DIP medical insurance payment reform, refined hospital management and increasingly stringent medical device supervision, medical institutions are transforming their procurement philosophy for high-value, technology-intensive core consumables such as brachytherapy needles. Procurement decisions no longer focus merely on unit price, but take comprehensive factors into account, including reliable clinical performance, long-term total cost of ownership, supply chain resilience, compliance risk control and timely technical support. Under such circumstances, bypassing multi-level distributors and establishing long-term strategic direct procurement partnerships with certified original manufacturers has become a rational choice to cut costs, boost efficiency, ensure safety and drive development.

1. Direct Factory Supply: Securing Quality and Safety at the First Mile

The traditional multi-distribution model creates multiple intermediaries between hospitals and actual manufacturers, leading to information loss and indirect quality supervision. Direct factory supply builds a transparent two-way communication channel.

• In-depth quality traceability and audit: Hospitals can directly assess the manufacturer's quality management system (e.g., ISO 13485 certification), production environment, R&D capabilities and change control procedures to build trust from the source. In the event of rare clinical feedback or adverse incidents, both parties can conduct rapid and targeted joint root cause analysis, tracing issues back to specific batches or production steps for efficient closed-loop resolution - a critical advantage for high-risk implantable devices.
• Guaranteed consistent performance: Continuous supply from a single manufacturer with stable technical capabilities ensures uniform dimensional accuracy, mechanical properties and compatibility with treatment equipment across different batches. Such consistency enables physicians and medical physicists to accumulate and replicate operational experience steadily, and avoids potential deviations in treatment plan execution caused by unstable device performance, which effectively reduces implicit clinical risks.

2. Optimizing Total Cost of Ownership (TCO) to Achieve Real Cost Reduction

In the traditional distribution model, every tier of distributors adds costs for logistics, warehousing, capital occupation, services and profits, which are ultimately reflected in hospitals' procurement prices. Direct factory supply creates value via supply chain restructuring.

• Eliminating intermediate markups: Products are delivered directly from manufacturing bases to hospital logistics centers or regional centralized operation platforms, featuring the shortest transportation routes and minimum intermediate expenses.
• Enabling refined inventory management: Based on historical consumption data, manufacturers work with hospitals to conduct accurate demand forecasting and even implement Vendor Managed Inventory (VMI). This maximizes hospital inventory turnover and substantially cuts capital occupation and warehousing management costs.
• Transparent benefits from volume-based group procurement: Long-term bulk strategic procurement contracts allow manufacturers to arrange production and material preparation according to stable orders. Preferential pricing stems from scale effects and improved supply chain efficiency, representing genuine value sharing rather than vicious price competition at the expense of product quality.

3. From Transactional Cooperation to Strategic Collaboration: Accessing Value-added Services Beyond Products

Original manufacturers deliver far more than qualified products delivered on schedule.

• Full compliance and registration support: Complete technical document packages are provided promptly, enabling seamless connection with hospital UDI systems, qualification reviews, medical insurance access and settlement procedures, and greatly reducing administrative burdens for hospital management departments.
• Professional clinical and technical support: Manufacturers deliver training on standard product use, offer optimization suggestions for compatibility with various brands of treatment planning systems and applicators, and participate in formulating and improving clinical Standard Operating Procedures (SOPs), so as to jointly enhance treatment quality and efficiency.
• Agile and reliable supply chain guarantee: As core strategic suppliers, manufacturers grant priority to order scheduling and offer rapid response channels for urgent orders. This ensures uninterrupted supply of consumables for clinical treatment plans and guarantees timely therapy for patients.

Conclusion

Adopting direct factory supply for brachytherapy needles represents an upgrade in procurement strategy. It transforms the hospital-supplier relationship from short-term zero-sum price negotiations into a long-term strategic partnership built on shared value and in-depth trust. Hospitals gain not only competitive procurement prices, but also full-lifecycle quality assurance, traceable safety commitments, a stable and efficient supply chain system and comprehensive professional technical support.

This allows hospitals to devote more resources and energy to their core mission of improving the clinical efficacy and academic research of oncology radiotherapy. Ultimately, it achieves a multi-win situation for patients, hospitals and manufacturers, and promotes the sound development of precision oncology radiotherapy.